

DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

DISTRICT OFFICE ADDRESS AND PHONE NUMBER FDA 1201 Main Street, Suite 7200 One Main Place Dallas, TX 75202-3908 Industry Information: www.fda.gov/oc/industry	DATE(S) OF INSPECTION 7/20-23; 26-28, 30; 8/3-4, 6/21
	FEI NUMBER 3016710945

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED
TO: Mr. Aaron M. Schneider, Director of Operations and co-owner

FIRM NAME Revive Rx, LLC dba Revive Rx Pharmacy	STREET ADDRESS 3831 Golf Drive Suite A
CITY, STATE AND ZIP CODE Houston, TX 77018	TYPE OF ESTABLISHMENT INSPECTED Producer of Sterile and Non-Sterile Drug Products

THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE.

DURING AN INSPECTION OF YOUR FIRM (I) (WE) OBSERVED:

OBSERVATION #1

The certification of the ISO 5 areas was inadequate. Specifically, smoke studies were not conducted to demonstrate unidirectional airflow and sweeping action over and away from sterile drug products under dynamic conditions.

OBSERVATION #2

The (b) (4) used for depyrogenation of product/equipment intended to be sterile were not lethal to heat-resistant microorganisms.


Specifically,

Your firm uses a (b) (4) to depyrogenate glassware used in the preparation of your firm's sterile injectable products. However, you do not use endotoxin indicators to ensure and verify that the (b) (4) and (b) (4) used to depyrogenate glassware is adequate.

OBSERVATION #3

Media fills are not performed that closely simulate aseptic production operations, incorporating, as appropriate, worst case activities and conditions that provide a challenge to aseptic operations.

Specifically, your Media Fill Challenge log sheet documents that a total of (b) (4) vials (b) (4) for control and (b) (4) for evaluation) will be used to conduct media fills. Review of media fills conducted since 8/2020 revealed that the media fills were not representative in that your firm failed to simulate actual production processes. For example, a typical lot of Human Chorionic Gonadotropin 12,000 IU Vial for Injection is (b) (4) vials.

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE 	EMPLOYEE(S) NAME AND TITLE (Print or Type) Stephen D. Brown, Investigator	DATE ISSUED 08/06/2021
--------------------------	--	--	---------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

DISTRICT OFFICE ADDRESS AND PHONE NUMBER FDA 1201 Main Street, Suite 7200 One Main Place Dallas, TX 75202-3908 Industry Information: www.fda.gov/oc/industry	DATE(S) OF INSPECTION 7/20-23; 26-28, 30; 8/3-4, 6/21 FEI NUMBER 3016710945
---	--

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED TO: Mr. Aaron M. Schneider, Director of Operations and co-owner	
FIRM NAME Revive Rx, LLC dba Revive Rx Pharmacy	STREET ADDRESS 3831 Golf Drive Suite A
CITY, STATE AND ZIP CODE Houston, TX 77018	TYPE OF ESTABLISHMENT INSPECTED Producer of Sterile and Non-Sterile Drug Products

In addition, your firm does not include an evaluation of the transfer of vials to and from the ISO 5 hood to the (b) (4). For example, your firm produces several (b) (4) products at your facility including Ipamorelin and HCG.


OBSERVATION #4


Product intended to be sterile was exposed to lower than ISO 5 classified quality air.

Specifically, your firm's procedure for (b) (4) finished drug products includes (b) (4) vials under the ISO 5 laminar flow hood and then removing these vials outside of the hood to transfer into the (b) (4).

OBSERVATION #5

Non-pharmaceutical grade components are used in the formulation of non-sterile drug products. For example, your firm uses (b) (4) produced via a (b) (4) process in-house which is used as a component in various non-sterile products. Your firm has no documentation to substantiate that the (b) (4) produced by (b) (4) meets, minimally, the specifications for (b) (4) USP. Some examples of drug products which use the (b) (4) include the following: PTD- DBM 0.03%/Sodium Valproate 5% 30 ml spray and Clindamycin 1.2%/Benzoyl Peroxide 5% Gel.



SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE 	EMPLOYEE(S) NAME AND TITLE (Print or Type) Stephen D. Brown, Investigator	DATE ISSUED 08/06/2021
--------------------------	--	--	---------------------------